Senator Bernie Sanders is set to lead a Senate investigation into the high prices charged by Novo Nordisk for its diabetes and anti-obesity medications Ozempic and Wegovy, The Financial Times’ Oliver Barnes reports. Sanders wrote to Novo Nordisk CEO Lars Fruergaard Jorgensen to inform him the U.S. committee that oversees healthcare is probing “the outrageously high prices” the company charges for the drugs, saying that the drugs “will not do any good for the millions of patients who cannot afford them.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO: